Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04247659
Other study ID # 2020-P002
Secondary ID
Status Recruiting
Phase Phase 4
First received
Last updated
Start date January 9, 2020
Est. completion date September 9, 2021

Study information

Verified date January 2020
Source The Second Hospital of Hebei Medical University
Contact Junzhao Cui, Dr
Phone +8615032189957
Email 1097709288@qq.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Susceptibility weighted imaging (SWI) technology has developed in the decade which is being a kind of cerebrovascular disease diagnostic tools in the clinical application, especially for paramagnetic material (such as DNA hemoglobin and hemosiderin) has a high sensitivity.

The change of the signal on SWI bases on the change of local oxygenated hemoglobin content in the blood and deaeration hemoglobin content ratio, which can be used to indirectly reflect the hypoxia group oxygen intake fraction (OEF) and cerebral metabolic rate. When the intracranial vascular occlusion, corresponding responsibility vascular blood flow area of brain tissue will occur hypoperfusion, brain tissue will improve the compensation in accordance with its own OEF, causing ischemia area inside the venous drainage of deaeration hemoglobin content ratio increases and the hypointensity on SWI ,which display the asymmetric cortical vessel sign (ACVS). Studies have suggested that ACVS is more prone to early neurological deterioration and has a poor long-term outcome. After recanalization of ischemic stroke, the presence of equal CVS(return to normal) on SWI is associated with a good clinical outcome. In addition, the relationship between ACVS grade and collateral circulation in patients with acute ischemic stroke has been studied. For patients with massive cerebral infarction, the relationship between ACVS on SWI and the clinical prognosis of cerebral edema and cerebral hemodynamics is not completely clear. In this study, the clinical data of patients with massive cerebral infarction will be analyzed to explore the relationship between ACVS, cerebral edema , cerebral hemodynamic and clinical prognosis.

Sodium aescinate is widely used in cerebral edema caused by cerebral hemorrhage or cerebral infarction.The main mechanism of sodium aescinate is anti - inflammatory, anti - exudate, anti - oxygen free radical, anti - edema, increase vein tension, improve blood circulation and nerve protection. In this study, investigators will investigate whether the application of sodium aescinate had an effect on ACVS on SWI in patients with massive cerebral infarction. Plasma s100-β, procalcitonin, neutrophil count, serum fibronectin, and endothelin-1 could predict cerebral edema in patients with cerebral infarction, this study will analyze the relationship between these markers and ACVS on SWI in patients with massive cerebral infarction.


Description:

Clinical data and plasma samples of patients diagnosed with massive cerebral infarction in the department of neurology of the second hospital of hebei medical university during 2020.1-2021.6 are collected.Clinical data include gender, age, TOAST classification, history of hypertension, diabetes and heart disease, head Computerized Tomography (CT), Magnetic Resonance Imaging(MRI), Diffusion-Weighted Imaging (DWI),Susceptibility weighted imaging SWI within 72 hours after onset, admission National Institute of Health stroke scale ( NIHSS) score, admission DWI-aspect score, Modified Rankin Scale (MRS) score on day 90 of onset.Venous blood will be taken within 72 hours of onset (and before the use of sodium aescinate) to detect serum s100-β, serum procalcitonin, plasma fibronectin, serum endothelin-1 by ELISA.The cortical vessel signs(CVSs)on SWI in the ischemic territory are classified as 'prominent' if there are more veins and/or larger veins with a greater signal loss than those in the opposite normal hemisphere, 'equal' if there are no significant differences in appearance of veins in the both cerebral hemispheres, and 'less' if the veins in the affected area are decreased compared to those in the normal cortex.

Patients with massive cerebral infarction to be included are randomly divided into experimental group and control group by random number table method.The experimental group is treated with sodium aescinate for injection on the basis of conventional treatment. The control group is not treated with sodium aescinate for injection.

This study will explore the relationship between asymmetric cortical vessel sign(ACVS) grade and baseline clinical data, serum factors associated with brain edema in patients with massive cerebral infarction.In addition,after 10 days of sodium aescinate injection, the CVS level of the experimental group will be compared with that of the control group.The difference of CVS grading before and after injection of sodium aescinate in the experimental group will be compared.Finally,the indexes with significance in single factor analysis will be screened out, and the factors related to prognosis of massive cerebral infarction will be further analyzed by multi-factor logistics regression.


Recruitment information / eligibility

Status Recruiting
Enrollment 150
Est. completion date September 9, 2021
Est. primary completion date June 9, 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- =18 years old

- Massive cerebral infarction within 72 hours from onset to admission

- Without other intracranial lesions or severe disease

- Agrees to participate in the study and sign the informed consent

Exclusion Criteria:

- Cerebral vascular malformation

- Cranial trauma and cranial surgery history

- With severe cardiac, hepatic and renal insufficiency

- With blood disorder, immune rheumatism (hormone abuse)

- Expected survival of less than 3 months

- Refuse to participate in this study

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
sodium aescinate
The main mechanism of sodium aescinate includes anti - inflammatory, anti - exudate anti - oxygen free radical ,anti - edema increased venous tension.The treatment course of sodium aescinate is 10 days,20mg/day, intravenous infusion.

Locations

Country Name City State
China Second hospital of hebei medical university Shijiazhuang Hebei

Sponsors (1)

Lead Sponsor Collaborator
The Second Hospital of Hebei Medical University

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary The correlation between asymmetric cortical vessel sign(ACVS) and age To evaluate whether ACVS and age are related 2 hour
Primary The correlation between asymmetric cortical vessel sign(ACVS) and sex To evaluate whether ACVS and sex are related 2 hour
Primary The correlation between asymmetric cortical vessel sign(ACVS) and TOAST subtypes Classification of causes of stroke --TOAST classification include Large-artery atherosclerosis( LAA),Cardioembolism(CE) ,Small-artery occlusion(SAO),Stroke of other determined cause(ODC) and Stroke of undetermined cause(UND). 2 hour
Primary The correlation between asymmetric cortical vessel sign(ACVS) and smoking history To evaluate whether ACVS and smoking history are related 2 hour
Primary The correlation between asymmetric cortical vessel sign(ACVS) and NIHSS score at admission The NIHSS score is 0 to 42 points. The higher the score, the more severe the nerve damage. 2 hour
Primary The correlation between asymmetric cortical vessel sign(ACVS) and mRS on 90 day The mRs score is used to measure the recovery of neurological function in patients after stroke. The mRs score is 0 to 6 points. The higher the score, the worse the neurological function recovery. 2 hour
Primary The correlation between asymmetric cortical vessel sign(ACVS) and DWI ASPECT ASPECT is a scale suitable for evaluating ischemic changes in the supply area of the middle cerebral artery with a total score of 10.A score of 10 indicates no signs of ischemia, while a score of 0 indicates extensive ischemia in the middle cerebral artery 2 hour
Primary The correlation between asymmetric cortical vessel sign(ACVS) and midline shift To evaluate whether ACVS and midline shift are related 2 hour
Primary The correlation between asymmetric cortical vessel sign(ACVS) and offending stenosis To evaluate whether ACVS and offending stenosis are related 2 hour
Primary The correlation between asymmetric cortical vessel sign(ACVS) and serum factor S100-B In acute ischemic stroke, the astroglial protein S100B is released into peripheral blood, reaching maximum serum concentrations between day 2 and day 4, correlating with infarct size. 2 hour
Primary The correlation between asymmetric cortical vessel sign(ACVS) and serum factor procalcitonin Procalcitonin is a stronger predictor of long-term functional outcome and mortality in patients with ischemic stroke. 2 hour
Primary The correlation between asymmetric cortical vessel sign(ACVS) and cellular-fibronectin A high plasma cellular-fibronectin concentration at admission is associated with the development of m-MCA infarction with high sensitivity and specificity. 2 hour
Primary The correlation between asymmetric cortical vessel sign(ACVS) and serum factor endothelin - 1 endothelin - 1 may be a diagnostic marker for development of severe brain edema in patients with acute ischemic stroke. 2 hour
Primary Changes of aescinin on asymmetric cortical vessel sign (ACVS). This study investigates whether the application of sodium aescinate has an effect on ACVS on SWI in patients with massive cerebral infarction. 2 hour
See also
  Status Clinical Trial Phase
Withdrawn NCT02551003 - Neuroprotective Effect of Autologous Cord Blood Combined With Therapeutic Hypothermia Following Neonatal Encephalopathy Phase 1/Phase 2
Completed NCT03281590 - Stroke and Cerebrovascular Diseases Registry
Recruiting NCT03605381 - MORbidity PRevalence Estimate In StrokE
Completed NCT00684515 - Trial to Assess the Safety of Vorapaxar in Japanese Subjects With Cerebral Infarction (P05005; MK-5348-017) Phase 2
Not yet recruiting NCT04082091 - Screening, Early Referral and Lifestyle Tailored E_prescription for Cardiovascular Prevention
Completed NCT01915368 - Determining Optimal Post-Stroke Exercise (DOSE) N/A
Terminated NCT01684462 - The Efficacy and Safety Study of ALbumin Therapy in Acute Ischemic Stroke Phase 2
Completed NCT00386191 - Safety and Efficacy of Clopidogrel for Cerebral Infarction Treatment Phase 4
Completed NCT00004734 - Vitamin Therapy for Prevention of Stroke Phase 3
Completed NCT02684825 - Detection of Silent Atrial Fibrillation aFter Ischemic StrOke N/A
Completed NCT02248233 - Nimodipine for Treating Acute Massive Cerebral Infarction Phase 4
Completed NCT02963545 - TSK (Tryptophan - Serotonin - Kynurenine) Biomarkers Assessment in Stroke N/A
Completed NCT02511249 - Early Determinants of Multidimensional Outcome at School Age After Neonatal Arterial Ischemic Stroke N/A
Completed NCT02101606 - Penumbral Based Novel Thrombolytic Therapy in Acute Ischemic Stroke Phase 2
Completed NCT00829361 - Stroke Telemedicine for Arizona Rural Residents Trial N/A
Completed NCT01500421 - Safty and Feasibility Study of Therapeutic Cooling in Acute Ischemic Stroke (COOLAID Øresund) Phase 2
Recruiting NCT01003470 - Treating Apoplectic Sequela With Acupuncture: a Randomized Controlled Study Phase 2
Terminated NCT00331890 - ICTUS Study: International Citicoline Trial on Acute Stroke Phase 3
Not yet recruiting NCT04696523 - Effect of Xenon on Brain Injury After Aneurysmal Subarachnoid Hemorrhage Phase 2
Completed NCT03741400 - Virtual Reality Glove for Hand and Arm Rehabilitation After Stroke N/A